Intended for healthcare professionals
NICE guidance on inclisiran should be reconsidered
The BMA and the Royal College of General Practitioners (RCGP) say they have “serious concerns” about the rollout of the new cholesterol lowering drug inclisiran in primary care in England.1
In September, the National Institute for Health and Care Excellence (NICE) recommended the treatment, calling it “a potential game changer in preventing thousands of people from dying prematurely from heart attacks and strokes.”23 The health and social care secretary Sajid Javid called it a “ground breaking” new drug. NHS England said that nurses will be able to administer inclisiran as an injection in GP surgeries across England.
Inclisiran is a novel treatment which uses RNA interference to boost the liver’s ability to remove low density lipoprotein (LDL) cholesterol from the blood. It is given by injection at zero, three, and six months and then twice a year for life.
In England it is recommended in patients who have a history of cardiovascular events and …
BMA Member Log In
If you have a subscription to The BMJ, log in:
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.
Buy this article
Respond to this article
Register for alerts
If you are unable to import citations, please contact technical support for your product directly (links go to external sites):
Thank you for your interest in spreading the word about The BMJ.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Read related article
See previous polls